

## A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fabry Disease

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- at least 18 years of age - diagnosis of Fabry disease - one or more of the following symptoms: i) cornea verticillata, ii) acroparesthesia, iii) anhidrosis, iv) angiokeratoma
- fully vaccinated for COVID- 19 per CDC guidance - additional requirements apply for cardiac and renal groups (study staff will review)

**Exclusion Criteria:**

- history of liver disease - current or history of use in the last six months of systemic steroids - other significant medical & mental health diagnosis (study staff will review)

### Conditions & Interventions

**Conditions:**

Rare Diseases

**Keywords:**

Fabry Disease

### More Information

**Description:** The purpose of this study is to test a new drug, called ST-920, to see if it is safe and if it works to treat Fabry disease. ST-920 is a gene therapy treatment, which means that ST-920 replaces the missing or broken gene you have because you have Fabry disease, with a version or copy that works.

**Study Contact:** Brenda Diethelm-Okita - dieth001@umn.edu

**Principal Investigator:** Chester Whitley, MD, PhD

**Phase:** PHASE1

**IRB Number:** STUDY00007094

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.